NanoViricides, Inc
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Other R&D services
- Other products or services
NanoViricides, Inc. (NYSE-Amer.: NNVC) is developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape despite constant changes. NV-387 would enable “emperic therapy” of viral infections - the patient would be prescribed NV-387 as soon as the physician expects a viral infection - just as how broad-spectrum antibiotics are given for bacterial infections. NV-387 is active against all tested viral infections in animal models, and escape of virus is not likely. NV-387 is entering Phase II clinical trials. NV-HHV-1 is a pan-herpesvirus drug candidate and NV-HIV-1 is a pan-HIV drug candidate moving towards IND.
Oral Drug Delivery: Additionally, the nanoviricide polymers can enable oral delivery of non-druggable or traditionally injectable drugs such as remdesivir and even peptides such as GLP-1 drugs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}